Plus Therapeutics, Inc. provided a business update on June 26, 2025, for its wholly-owned subsidiary, CNSide Diagnostics, LLC. The company announced that the U.S. commercial rollout of its proprietary CNSide Cerebrospinal Fluid (CSF) Assay Platform will begin in the second half of 2025.
The first test to be commercialized, CNSide CSF Tumor Cell Enumeration (TCE), has a total addressable market estimated to be $6 billion in the U.S. The CNSide platform has demonstrated high sensitivity (92%) and specificity (95%) in over 11,000 tests performed since 2020, influencing treatment decisions in 90% of cases.
The company has established infrastructure for a scalable centralized testing laboratory in Houston, TX, and is executing its commercial market access strategy. Initial launch is planned for Texas in the second half of 2025, with rapid expansion into additional states in late 2025 and 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.